| Zacks Company Profile for Prothena Corporation plc (PRTA : NSDQ) |
|
|
| |
| • Company Description |
| Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
Number of Employees: 82 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $26.30 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 523,616 shares |
| Shares Outstanding: 46.81 (millions) |
| Market Capitalization: $1,231.00 (millions) |
| Beta: 1.37 |
| 52 Week High: $79.75 |
| 52 Week Low: $21.30 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-27.25% |
-20.58% |
| 12 Week |
-21.89% |
-15.58% |
| Year To Date |
-46.76% |
-36.94% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS
-
DUBLIN,L2 D02 VK60
IRL |
ph: 011-353-1236-2500
fax: 353-1902-3510 |
ellen.rose@prothena.com |
http://www.prothena.com |
|
|
| |
| • General Corporate Information |
Officers
Gene G. Kinney - Chief Executive Officer; President and Director
Lars G. Ekman - Chairman
Tran B. Nguyen - Chief Strategy Officer and Chief Financial Officer
Karin L. Walker - Chief Accounting Officer
Paula K. Cobb - Director
|
|
Peer Information
Prothena Corporation plc (CORR.)
Prothena Corporation plc (RSPI)
Prothena Corporation plc (CGXP)
Prothena Corporation plc (BGEN)
Prothena Corporation plc (GTBP)
Prothena Corporation plc (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G72800108
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
|
|
Share - Related Items
Shares Outstanding: 46.81
Most Recent Split Date: (:1)
Beta: 1.37
Market Capitalization: $1,231.00 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.50 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-2.53 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 5.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/04/22 |
|
|
|
| |
